{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:58:29Z","timestamp":1769169509204,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40618-019-01058-x","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T17:51:06Z","timestamp":1557942666000},"page":"1443-1450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9651-7650","authenticated-orcid":false,"given":"I.","family":"Mazarico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Capel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gim\u00e9nez-Palop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Berges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Luchtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Fern\u00e1ndez-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. J.","family":"De Pedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Caix\u00e0s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rigla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"issue":"6","key":"1058_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","volume":"41","author":"P Chalan","year":"2018","unstructured":"Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P (2018) Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest 41(6):625\u2013638. \n                    https:\/\/doi.org\/10.1007\/s40618-017-0778-8","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1058_CR2","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","volume":"24","author":"P Cukier","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24(12):T331\u2013T347. \n                    https:\/\/doi.org\/10.1530\/ERC-17-0358","journal-title":"Endocr Relat Cancer"},{"issue":"suppl_4","key":"1058_CR3","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 28(suppl_4):iv119\u2013iv142. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"1058_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0984-z","author":"RM Ruggeri","year":"2018","unstructured":"Ruggeri RM, Campenn\u00ec A, Giuffrida G et al (2018) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest. \n                    https:\/\/doi.org\/10.1007\/s40618-018-0984-z","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1058_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA (2017) Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat Med 23(5):540\u2013547. \n                    https:\/\/doi.org\/10.1038\/nm.4321","journal-title":"Nat Med"},{"issue":"4","key":"1058_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98(4):1361\u20131375. \n                    https:\/\/doi.org\/10.1210\/jc.2012-4075","journal-title":"J Clin Endocrinol Metab"},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) Induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49. \n                    https:\/\/doi.org\/10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7\u201318. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.003","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1058_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","volume":"41","author":"F Guaraldi","year":"2018","unstructured":"Guaraldi F, La Selva R, Sam\u00e0 MT et al (2018) Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 41(5):549\u2013556. \n                    https:\/\/doi.org\/10.1007\/s40618-017-0772-1","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"1058_CR10","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S et al (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102(8):2770\u20132780. \n                    https:\/\/doi.org\/10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1058_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 28(3):583\u2013589. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"1","key":"1058_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"6","key":"1058_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/thy.1997.7.891","volume":"7","author":"LKH Koh","year":"2009","unstructured":"Koh LKH, Greenspan FS, Yeo PPB (2009) Interferon-\u03b1 induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7(6):891\u2013896. \n                    https:\/\/doi.org\/10.1089\/thy.1997.7.891","journal-title":"Thyroid"},{"issue":"9","key":"1058_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1055\/s-2007-1003353","volume":"24","author":"R Vassilopoulou-Sellin","year":"1992","unstructured":"Vassilopoulou-Sellin R, Sella A, Dexeus FH, Theriault RL, Pololoff DA (1992) Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res 24(9):434\u2013438. \n                    https:\/\/doi.org\/10.1055\/s-2007-1003353","journal-title":"Horm Metab Res"},{"issue":"3","key":"1058_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/js.2017-00432","volume":"2","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T, Iwama S, Yasuda Y et al (2018) Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc 2(3):241\u2013251. \n                    https:\/\/doi.org\/10.1210\/js.2017-00432","journal-title":"J Endocr Soc"},{"key":"1058_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12902-018-0267-x","volume":"18","author":"S Yano","year":"2018","unstructured":"Yano S, Ashida K, Nagata H et al (2018) Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma. BMC Endocr Disord 18:36. \n                    https:\/\/doi.org\/10.1186\/s12902-018-0267-x","journal-title":"BMC Endocr Disord"},{"key":"1058_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00813","author":"C Iadarola","year":"2019","unstructured":"Iadarola C, Croce L, Quaquarini E et al (2019) Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis. Front Endocr (Lausanne). \n                    https:\/\/doi.org\/10.3389\/fendo.2018.00813","journal-title":"Front Endocr (Lausanne)"},{"issue":"4","key":"1058_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0042-119528","volume":"125","author":"M Alhusseini","year":"2017","unstructured":"Alhusseini M, Samantray J (2017) Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms. Exp Clin Endocrinol Diabetes 125(4):267\u2013269. \n                    https:\/\/doi.org\/10.1055\/s-0042-119528","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"11","key":"1058_CR19","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J de Filette","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M et al (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101(11):4431\u20134439. \n                    https:\/\/doi.org\/10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"key":"1058_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4560","author":"S Orlov","year":"2015","unstructured":"Orlov S, Salari F, Kashat L, Walfish PG (2015) Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. \n                    https:\/\/doi.org\/10.1210\/jc.2014-4560","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1058_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"Morganstein DL, Lai Z, Spain L et al (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86(4):614\u2013620. \n                    https:\/\/doi.org\/10.1111\/cen.13297","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1058_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","volume":"35","author":"J Dulos","year":"2012","unstructured":"Dulos J, Carven GJ, van Boxtel SJ et al (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35(2):169\u2013178. \n                    https:\/\/doi.org\/10.1097\/CJI.0b013e318247a4e7","journal-title":"J Immunother"},{"issue":"6","key":"1058_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40618-014-0083-8","volume":"37","author":"M Rotondi","year":"2014","unstructured":"Rotondi M, Coperchini F, Magri F, Chiovato L (2014) Serum-negative autoimmune thyroiditis: what\u2019s in a name? J Endocrinol Invest 37(6):589\u2013591. \n                    https:\/\/doi.org\/10.1007\/s40618-014-0083-8","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1058_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","volume":"5","author":"TE Angell","year":"2018","unstructured":"Angell TE, Min L, Wieczorek TJ, Hodi FS (2018) Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma HHS public access. Genes Dis 5(1):46\u201348. \n                    https:\/\/doi.org\/10.1016\/j.gendis.2017.11.002","journal-title":"Genes Dis"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01058-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01058-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01058-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T23:21:43Z","timestamp":1589412103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01058-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01058-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]},"assertion":[{"value":"17 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest that could prejudice the impartiality of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institution and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}